



Toxicological Profile for Chloromethane

September 2023



U.S. Department of Health and Human Services
Agency for Toxic Substances and Disease Registry

CS274127-A

DISCLAIMER

Use of trade names is for identification only and does not imply endorsement by the Agency for Toxic Substances and Disease Registry, the Public Health Service, or the U.S. Department of Health and Human Services.

FOREWORD

This toxicological profile is prepared in accordance with guidelines* developed by the Agency for Toxic Substances and Disease Registry (ATSDR) and the Environmental Protection Agency (EPA). The original guidelines were published in the *Federal Register* on April 17, 1987. Each profile will be revised and republished as necessary.

The ATSDR toxicological profile succinctly characterizes the toxicologic and adverse health effects information for these toxic substances described therein. Each peer-reviewed profile identifies and reviews the key literature that describes a substance's toxicologic properties. Other pertinent literature is also presented, but is described in less detail than the key studies. The profile is not intended to be an exhaustive document; however, more comprehensive sources of specialty information are referenced.

The focus of the profiles is on health and toxicologic information; therefore, each toxicological profile begins with a relevance to public health discussion which would allow a public health professional to make a real-time determination of whether the presence of a particular substance in the environment poses a potential threat to human health. The adequacy of information to determine a substance's health effects is described in a health effects summary. Data needs that are of significance to the protection of public health are identified by ATSDR.

Each profile includes the following:

- (A) The examination, summary, and interpretation of available toxicologic information and epidemiologic evaluations on a toxic substance to ascertain the levels of significant human exposure for the substance due to associated acute, intermediate, and chronic exposures;
- (B) A determination of whether adequate information on the health effects of each substance is available or in the process of development to determine levels of exposure that present a significant risk to human health of acute, intermediate, and chronic health effects; and
- (C) Where appropriate, identification of toxicologic testing needed to identify the types or levels of exposure that may present significant risk of adverse health effects in humans.

The principal audiences for the toxicological profiles are health professionals at the Federal, State, and local levels; interested private sector organizations and groups; and members of the public.

This profile reflects ATSDR's assessment of all relevant toxicologic testing and information that has been peer-reviewed. Staffs of the Centers for Disease Control and Prevention and other Federal scientists have also reviewed the profile. In addition, this profile has been peer-reviewed by a nongovernmental panel and was made available for public review. Final responsibility for the contents and views expressed in this toxicological profile resides with ATSDR.



Christopher M. Reh, Ph.D.

Associate Director

Agency for Toxic Substances and Disease Registry
Centers for Disease Control and Prevention

*Legislative Background

The toxicological profiles are developed under the Comprehensive Environmental Response, Compensation, and Liability Act of 1980, as amended (CERCLA or Superfund). CERCLA section 104(i)(1) directs the Administrator of ATSDR to "...effectuate and implement the health related authorities" of the statute. This includes the preparation of toxicological profiles for hazardous substances most commonly found at facilities on the CERCLA National Priorities List (NPL) and that pose the most significant potential threat to human health, as determined by ATSDR and the EPA. Section 104(i)(3) of CERCLA, as amended, directs the Administrator of ATSDR to prepare a toxicological profile for each substance on the list. In addition, ATSDR has the authority to prepare toxicological profiles for substances not found at sites on the NPL, in an effort to "...establish and maintain inventory of literature, research, and studies on the health effects of toxic substances" under CERCLA Section 104(i)(1)(B), to respond to requests for consultation under section 104(i)(4), and as otherwise necessary to support the site-specific response actions conducted by ATSDR.

VERSION HISTORY

Date	Description
September 2023	Final toxicological profile released
January 2022	Draft for public comment toxicological profile released
June 2009	Addendum to the toxicological profile released
December 1998	Final toxicological profile released

CONTRIBUTORS & REVIEWERS

CHEMICAL MANAGER TEAM

Sam Keith, M.S., C.H.P. (Lead)
Breanna Alman, M.P.H.

ATSDR, Office of Innovation and Analytics,
Toxicology Section, Atlanta, GA

Lauren Brown, M.S., D.A.B.T.
Kaley Beins, M.P.H.
Hannah Derrick, B.S.
Kerry Diskin, Ph.D.
Andrea Chiger, M.P.H.
Mary Juergens, M.P.H.
Meghan Lynch, M.P.H., DSc

Abt Associates, Cambridge, MA

Kimberly Zaccaria, Ph.D., D.A.B.T.
Deborah Herber, Ph.D.
Mario Citra, Ph.D.
Christina Coley, B.S.

SRC, Inc., North Syracuse, NY

REVIEWERS

Interagency Minimal Risk Level Workgroup:

Includes ATSDR; National Center for Environmental Health (NCEH); National Institute for Occupational Safety and Health (NIOSH); U.S. Environmental Protection Agency (EPA); National Toxicology Program (NTP).

Additional reviews for science and/or policy:

ATSDR, Office of Community Health Hazard Assessment; ATSDR, Office of Capacity Development and Applied Prevention Science; ATSDR, Office of Science; NCEH, Division of Laboratory Sciences; NCEH, Division of Environmental Health Sciences and Practice; EPA.

PEER REVIEWERS

Peer Reviewers for the full profile:

1. Kyle Steenland, Ph.D., Professor, Department of Environmental Health Professor, Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, Georgia
2. James S. Bus Ph.D., DABT, Fellow ATS, Senior Managing Scientist, Center for Toxicology and Mechanistic Biology, Midland, Michigan
3. Dale Hattis, Ph.D., George Perkins Marsh Institute, Clark University, Worcester, Massachusetts

Peer Reviewers for the intermediate-duration inhalation MRL:

1. Lili Tang, Ph.D., Associate Professor, Biological Sciences Department, University of Georgia, Athens, Georgia
2. James S. Bus Ph.D., DABT, Senior Managing Scientist, Center for Toxicology and Mechanistic Biology, Midland, Michigan
3. Vilhjálmur Rafnsson MD, Ph.D., Professor in Preventive Medicine, University of Iceland, Reykjavik, Iceland

These experts collectively have knowledge of toxicology, chemistry, and/or health effects. All reviewers were selected in conformity with Section 104(I)(13) of the Comprehensive Environmental Response, Compensation, and Liability Act, as amended.

ATSDR scientists review peer reviewers' comments and determine whether changes will be made to the profile based on comments. The peer reviewers' comments and responses to these comments are part of the administrative record for this compound.

The listing of peer reviewers should not be understood to imply their approval of the profile's final content. The responsibility for the content of this profile lies with ATSDR.

CONTENTS

DISCLAIMER	ii
FOREWORD	iii
VERSION HISTORY	v
CONTRIBUTORS & REVIEWERS	vi
CONTENTS.....	viii
LIST OF FIGURES	x
LIST OF TABLES.....	xi
CHAPTER 1. RELEVANCE TO PUBLIC HEALTH	1
1.1 OVERVIEW AND U.S. EXPOSURES	1
1.2 SUMMARY OF HEALTH EFFECTS.....	2
1.3 MINIMAL RISK LEVELS (MRLs)	7
CHAPTER 2. HEALTH EFFECTS.....	9
2.1 INTRODUCTION.....	9
2.2 DEATH	57
2.3 BODY WEIGHT	59
2.4 RESPIRATORY.....	60
2.5 CARDIOVASCULAR.....	62
2.6 GASTROINTESTINAL.....	64
2.7 HEMATOLOGICAL	64
2.8 MUSCULOSKELETAL	66
2.9 HEPATIC	66
2.10 RENAL	69
2.11 DERMAL	71
2.12 OCULAR	71
2.13 ENDOCRINE.....	72
2.14 IMMUNOLOGICAL	73
2.15 NEUROLOGICAL.....	73
2.16 REPRODUCTIVE	78
2.17 DEVELOPMENTAL	80
2.18 OTHER NONCANCER.....	81
2.19 CANCER.....	81
2.20 GENOTOXICITY	83
2.21 MECHANISMS OF TOXICITY	85
CHAPTER 3. TOXICOKINETICS, SUSCEPTIBLE POPULATIONS, BIOMARKERS, CHEMICAL INTERACTIONS.....	87
3.1 TOXICOKINETICS.....	87
3.1.1 Absorption.....	87
3.1.2 Distribution	88
3.1.3 Metabolism.....	89
3.1.4 Excretion	94
3.1.5 Physiologically Based Pharmacokinetic (PBPK)/Pharmacodynamic (PD) Models	95
3.1.6 Animal-to-Human Extrapolations	96
3.2 CHILDREN AND OTHER POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE.....	96
3.3 BIOMARKERS OF EXPOSURE AND EFFECT	99

3.3.1	Biomarkers of Exposure.....	100
3.3.2	Biomarkers of Effect	101
3.4	INTERACTIONS WITH OTHER CHEMICALS	102
CHAPTER 4. CHEMICAL AND PHYSICAL INFORMATION		104
4.1	CHEMICAL IDENTITY	104
4.2	PHYSICAL AND CHEMICAL PROPERTIES	105
CHAPTER 5. POTENTIAL FOR HUMAN EXPOSURE.....		107
5.1	OVERVIEW	107
5.2	PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL	109
5.2.1	Production	109
5.2.2	Import/Export.....	111
5.2.3	Use	112
5.2.4	Disposal.....	112
5.3	RELEASES TO THE ENVIRONMENT.....	113
5.3.1	Air	115
5.3.2	Water.....	118
5.3.3	Soil	119
5.4	ENVIRONMENTAL FATE	120
5.4.1	Transport and Partitioning.....	120
5.4.2	Transformation and Degradation	121
5.5	LEVELS IN THE ENVIRONMENT	125
5.5.1	Air	126
5.5.2	Water.....	129
5.5.3	Sediment and Soil	132
5.5.4	Other Media	133
5.6	GENERAL POPULATION EXPOSURE.....	134
5.7	POPULATIONS WITH POTENTIALLY HIGH EXPOSURES	136
CHAPTER 6. ADEQUACY OF THE DATABASE		137
6.1	EXISTING INFORMATION ON HEALTH EFFECTS	137
6.2	IDENTIFICATION OF DATA NEEDS.....	139
6.3	ONGOING STUDIES.....	148
CHAPTER 7. REGULATIONS AND GUIDELINES		149
CHAPTER 8. REFERENCES		151
APPENDICES		
APPENDIX A. ATSDR MINIMAL RISK LEVEL WORKSHEETS		A-1
APPENDIX B. LITERATURE SEARCH FRAMEWORK FOR CHLOROMETHANE		B-1
APPENDIX C. FRAMEWORK FOR ATSDR'S SYSTEMATIC REVIEW OF HEALTH EFFECTS DATA FOR CHLOROMETHANE.....		C-1
APPENDIX D. USER'S GUIDE.....		D-1
APPENDIX E. QUICK REFERENCE FOR HEALTH CARE PROVIDERS		E-1
APPENDIX F. GLOSSARY		F-1
APPENDIX G. ACRONYMS, ABBREVIATIONS, AND SYMBOLS.....		G-1

LIST OF FIGURES

1-1. Health Effects Found in Animals Following Inhalation Exposure to Chloromethane	4
1-2. Summary of Sensitive Targets of Chloromethane – Inhalation.....	7
2-1. Overview of the Number of Studies Examining Chloromethane Health Effects	12
2-2. Levels of Significant Exposure to Chloromethane – Inhalation.....	40
2-3. Level of Significant Exposure of Animals to Chloromethane – Oral.....	56
3-1. Proposed Scheme for Metabolism of Chloromethane	93
5-1. Number of NPL Sites with Chloromethane Contamination	107
6-1. Summary of Existing Health Effects Studies on Chloromethane by Route and Endpoint.....	138

LIST OF TABLES

1-1. Minimal Risk Levels (MRLs) for Chloromethane	8
2-1. Health Effects Evaluated in Humans Exposed to Chloromethane—Epidemiological Studies	13
2-2. Levels of Significant Exposure to Chloromethane – Inhalation.....	15
2-3. Levels of Significant Exposure of Animals to Chloromethane – Oral.....	55
2-4. Genotoxicity of Chloromethane <i>In Vitro</i>	83
2-5. Genotoxicity of Chloromethane <i>In Vivo</i>	84
4-1. Chemical Identity of Chloromethane.....	104
4-2. Physical and Chemical Properties of Chloromethane.....	105
5-1. Facilities that Produce, Process, or Use Chloromethane	110
5-2. Releases to the Environment from Facilities that Produce, Process, or Use Chloromethane.....	114
5-3. Estimated Annual Chloromethane Emissions in the United States	117
5-4. Lowest Limit of Detection Based on Standards	125
5-5. Chloromethane Levels in Water, Soil, and Air of National Priorities List (NPL) Sites	125
5-6. Summary of Annual Concentration of Chloromethane Measured in Ambient Air at Locations Across the United States.....	126
5-7. Outdoor Air Monitoring Data for Chloromethane.....	127
5-8. Surface Water Monitoring Data for Chloromethane	130
5-9. Groundwater Monitoring Data for Chloromethane	131
5-10. Drinking Water Monitoring Data for Chloromethane	131
5-11. Landfill Leachate and Effluent Monitoring Data for Chloromethane	132
7-1. Regulations and Guidelines Applicable to Chloromethane	149